Log in to save to my catalogue

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year surv...

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year surv...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_2b98c18ea9d84e45baec87cc1752497f

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

No prospective data were available prior to 2021 to inform selection between combination BRAF and MEK inhibition versus dual blockade of programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) as first-line treatment options for
BRAFV
600-mutant melanoma. SECOMBIT (NCT02631447) was a randomized, three-arm, noncomp...

Alternative Titles

Full title

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_2b98c18ea9d84e45baec87cc1752497f

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_2b98c18ea9d84e45baec87cc1752497f

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/s41467-023-44475-6

How to access this item